Popular Trials
BTK Inhibitor
Ibrutinib + Pembrolizumab for Leukemia and Lymphoma
Recruiting2 awardsPhase 1 & 2
New York, New York
This trial will help determine the best dose of ibrutinib in combination with pembrolizumab for patients with CLL or MCL that has relapsed or progressed after prior therapy. The safety of this combination will also be studied.
Radiation Therapy
Orbital Radiation Therapy for Lymphoma
Recruiting1 awardPhase 2
Houston, Texas
This trial is studying ultra low dose orbital radiation therapy to treat stage I-IV low grade B-cell lymphoma or mantle cell lymphoma involving the orbit of the eye. This type of radiation therapy uses external beam radiation to destroy cancer cells and may be effective with fewer side effects.
Immunomodulatory Agent
Ibrutinib + Lenalidomide + Rituximab for Lymphoma
Recruiting1 awardPhase 1
Hackensack, New Jersey
This trial tests a combination of three drugs (ibrutinib, lenalidomide, and rituximab) in patients with mantle cell lymphoma who have not responded to other treatments. Ibrutinib stops cancer cell growth, lenalidomide boosts the immune system, and rituximab helps the immune system target cancer cells. Lenalidomide and rituximab have shown significant activity in mantle cell lymphoma, both as monotherapies and in combination. The goal is to find the best dose and see how well this combination works.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Acalabrutinib for Mantle Cell Lymphoma
Recruiting1 awardPhase 2
Tampa, Florida
This trial will help researchers learn more about how safe and effective ACP-196 is for treating people with a certain type of cancer that has come back or does not respond to other treatments.
Popular Filters
Trials for MCL Patients
LOXO-338 for Blood Cancers
Recruiting1 awardPhase 1
Miami, Florida
This trial is testing a new drug, LOXO-338, to treat advanced blood cancer in patients who haven't responded to standard treatments. If effective alone, it will also be tested with another drug, pirtobrutinib, to see if the combination works better.
CDK4/6 Inhibitor
Palbociclib + Ibrutinib for Mantle Cell Lymphoma
Recruiting1 awardPhase 2
Duarte, California
This trial tests a combination of two drugs, palbociclib and ibrutinib, for patients with mantle cell lymphoma who have previously received treatment. Palbociclib stops cancer cells from dividing, while ibrutinib blocks signals that help cancer cells grow. The goal is to see how well this combination works in slowing down or stopping the cancer.
Kinase Inhibitor
Ibrutinib + Rituximab for Mantle Cell Lymphoma
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing ibrutinib and rituximab as a treatment for mantle cell lymphoma. Ibrutinib may stop the growth of cancer cells by blocking enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may find cancer cells and help kill them.
Aurora Kinase Inhibitor
Triple Therapy for Lymphoma
Recruiting1 awardPhase 1
Bronx, New York
This trial is testing the side effects and best dose of two drugs, alisertib and bortezomib, when given together with rituximab to treat patients with mantle cell lymphoma or B-cell low grade non-Hodgkin lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory).
Trials for Lymphoma Patients
LOXO-338 for Blood Cancers
Recruiting1 awardPhase 1
Miami, Florida
This trial is testing a new drug, LOXO-338, to treat advanced blood cancer in patients who haven't responded to standard treatments. If effective alone, it will also be tested with another drug, pirtobrutinib, to see if the combination works better.
Monoclonal Antibodies
Combination Therapy for Mantle Cell Lymphoma
Recruiting1 awardPhase 2
Anchorage, Alaska
This trial is studying a combination of rituximab, bortezomib, bendamustine, and lenalidomide to see how well it works compared with rituximab and bendamustine, followed by rituximab alone or with lenalidomide, in treating mantle cell lymphoma.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Zanubrutinib + Rituximab vs Bendamustine + Rituximab for Mantle Cell Lymphoma
Recruiting2 awardsPhase 3
Orange, California
This trial will compare two treatments for mantle cell lymphoma in people who are not eligible for stem cell transplantation. One treatment is zanubrutinib plus rituximab, and the other is bendamustine plus rituximab. The trial will compare how well each treatment works and how safe each is.
Histone Deacetylase Inhibitor
Abexinostat + Ibrutinib for Lymphoma
Recruiting1 awardPhase 1
Basking Ridge, New Jersey
This trial tests if combining abexinostat and ibrutinib can safely stop cancer growth in patients by blocking enzymes and proteins that help cancer cells grow and survive. Ibrutinib is a medication approved for treating various cancers.
Trials for CCND1 Positive Patients
CDK4/6 Inhibitor
Palbociclib + Ibrutinib for Mantle Cell Lymphoma
Recruiting1 awardPhase 2
Duarte, California
This trial tests a combination of two drugs, palbociclib and ibrutinib, for patients with mantle cell lymphoma who have previously received treatment. Palbociclib stops cancer cells from dividing, while ibrutinib blocks signals that help cancer cells grow. The goal is to see how well this combination works in slowing down or stopping the cancer.
Kinase Inhibitor
Ibrutinib + Rituximab for Mantle Cell Lymphoma
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing ibrutinib and rituximab as a treatment for mantle cell lymphoma. Ibrutinib may stop the growth of cancer cells by blocking enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may find cancer cells and help kill them.
Monoclonal Antibodies
Combination Therapy for Mantle Cell Lymphoma
Recruiting1 awardPhase 2
Anchorage, Alaska
This trial is studying a combination of rituximab, bortezomib, bendamustine, and lenalidomide to see how well it works compared with rituximab and bendamustine, followed by rituximab alone or with lenalidomide, in treating mantle cell lymphoma.
Bruton's Tyrosine Kinase Inhibitor
Ibrutinib for Mantle Cell Lymphoma
Recruiting2 awardsPhase 2
Houston, Texas
This trial will study how well ibrutinib works in treating people with untreated high risk smoldering mental cell lymphoma. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Trials for CD20 Positive Patients
Kinase Inhibitor
Ibrutinib + Rituximab for Mantle Cell Lymphoma
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing ibrutinib and rituximab as a treatment for mantle cell lymphoma. Ibrutinib may stop the growth of cancer cells by blocking enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may find cancer cells and help kill them.
Bruton's Tyrosine Kinase Inhibitor
Ibrutinib for Mantle Cell Lymphoma
Recruiting2 awardsPhase 2
Houston, Texas
This trial will study how well ibrutinib works in treating people with untreated high risk smoldering mental cell lymphoma. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase 3 Trials
Bruton's Tyrosine Kinase (BTK) Inhibitor
Zanubrutinib + Rituximab vs Bendamustine + Rituximab for Mantle Cell Lymphoma
Recruiting2 awardsPhase 3
Orange, California
This trial will compare two treatments for mantle cell lymphoma in people who are not eligible for stem cell transplantation. One treatment is zanubrutinib plus rituximab, and the other is bendamustine plus rituximab. The trial will compare how well each treatment works and how safe each is.
Kinase Inhibitor
Long-term Ibrutinib for Lymphoma
Recruiting2 awardsPhase 3
Lebanon, New Hampshire
This trial aims to provide ongoing access to ibrutinib for patients who have benefited from it in previous studies. Ibrutinib is an oral medication that blocks a protein involved in cancer growth, helping to slow or stop the disease. The study will monitor safety and effectiveness over time. Ibrutinib has been studied extensively and is used to treat various B cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma.
Trials With No Placebo
LOXO-338 for Blood Cancers
Recruiting1 awardPhase 1
Miami, Florida
This trial is testing a new drug, LOXO-338, to treat advanced blood cancer in patients who haven't responded to standard treatments. If effective alone, it will also be tested with another drug, pirtobrutinib, to see if the combination works better.
CDK4/6 Inhibitor
Palbociclib + Ibrutinib for Mantle Cell Lymphoma
Recruiting1 awardPhase 2
Duarte, California
This trial tests a combination of two drugs, palbociclib and ibrutinib, for patients with mantle cell lymphoma who have previously received treatment. Palbociclib stops cancer cells from dividing, while ibrutinib blocks signals that help cancer cells grow. The goal is to see how well this combination works in slowing down or stopping the cancer.
Kinase Inhibitor
Ibrutinib + Rituximab for Mantle Cell Lymphoma
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing ibrutinib and rituximab as a treatment for mantle cell lymphoma. Ibrutinib may stop the growth of cancer cells by blocking enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may find cancer cells and help kill them.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.